Catalyst Calendar
Scope

Sun, Jun 14, 2026

1 updates
UPB
10:00 AM

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced clinically meaningful improvements across key secondary endpoints, including 72% in

Presentation / Abstract • Phase 2Oral presentation Sun, Jun 14, 2026upstreambio.com

Mon, Jun 8, 2026

1 updates
UPB
7:00 AM

Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026

WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that additional data from its Phase 2 VIBRANT trial of verekitug in

Presentation / Abstract • Phase 2Oral presentation Sun, Jun 14, 2026, 3:15 PM TRTupstreambio.com

Wed, Jun 3, 2026

1 updates

Mon, May 18, 2026

1 updates
UPB
11:30 AM

Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma – – Verekitug led to improvements in nasal polyp score (NPS) in participants with

Presentation / Abstract • Phase 2ATS poster presentation Mon, May 18, 2026upstreambio.com

Wed, May 13, 2026

1 updates
UPB
7:01 AM

Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP – – End-of-Phase 2 meetings with FDA planned for mid-2026; Phase 3 initiations in both indications expected in Q1 2027 – – Phase 2 VENTURE trial in

Presentation / Abstract • Phase 2ATS abstract release Fri, May 15, 2026upstreambio.com

Fri, Apr 17, 2026

1 updates